My research spans four connected domains: genomics, computational drug discovery, immunoinformatics, and wet-lab experimental biology. I pair molecular techniques with computational workflows to investigate disease-associated variants, design therapeutic candidates, and build immunoinformatics-driven vaccines.
Identify disease-associated MMP variants using combined wet-lab and computational workflows.
Methods
Outcome. Novel variants identified across a Bangladeshi study population.
Build a high-throughput WES workflow for disease-associated SNPs and indels.
Methods
Outcome. A reproducible pipeline from raw reads to annotated, filtered variants.
Screen population-level SNPs to identify risk-associated loci in breast cancer.
Methods
Outcome. Candidate risk loci prioritised for downstream study.
Identify lead compounds targeting the CHIKV RNA-dependent RNA polymerase.
Methods
Outcome. First-author Q1 publication identifying multi-target RdRp inhibitor candidates.
Investigate natural compounds targeting P53 for therapeutic potential.
Methods
Outcome. Two lead compounds validated for binding affinity and bioactivity.
Identify small molecules targeting viral membrane and polymerase proteins.
Methods
Outcome. A shortlist of optimised candidates for further evaluation.
Generate epitope-based vaccine candidates through a complete immunoinformatics pipeline.
Methods
Outcome. First-author Q1 publication presenting a validated vaccine construct.
Computational antigen discovery and epitope prioritisation for C. trachomatis.
Methods
Outcome. A prioritised antigen set proposed for vaccine development.
Identify conserved epitopes for rational vaccine design.
Methods
Outcome. A conserved multi-epitope construct with simulated immune response.
Gain hands-on experience with Sanger workflows and next-generation sequencing.
Methods
Outcome. Practical command of core sequencing instrumentation.
Experimentally validate two lead compounds with high binding affinity to P53.
Methods
Outcome. Laboratory results consistent with the computational binding predictions.
Run a complete bioinformatics pipeline for antiviral drug discovery.
Methods
Outcome. Foundational work that led to the first-author CHIKV publication.